Anticoagulation Management After Total Hysterectomy in Patients with Prosthetic Mitral Valve
Introduction to Anticoagulation
- The American College of Chest Physicians recommends initiating unfractionated heparin (UFH) ≥24 hours after surgery to reduce the risk of postoperative bleeding in patients with prosthetic mitral valves undergoing total hysterectomy 1, 2, 3
Considerations for Perioperative Anticoagulation
Thrombotic Risk in Prosthetic Mitral Valves
- Patients with mechanical mitral valves are considered high-risk for thrombotic complications, with a higher risk of thromboembolic events compared to those with valves in the aortic position 4, 5
Postoperative Anticoagulation Management
- For patients receiving bridging therapy with intravenous UFH at therapeutic doses, it is suggested to resume UFH ≥24 hours after surgery instead of within the first 24 hours 1, 2, 3
- When resuming UFH postoperatively, it is recommended to avoid bolus administration and start with a lower-intensity infusion, associated with a lower target activated partial thromboplastin time (aPTT) than that used for full-dose UFH initiation 3
Algorithm for Managing Patients with Prosthetic Mitral Valves
Postoperative Risk Assessment
- Evaluate the patient's hemodynamic stability 4
- Verify the absence of active bleeding at the surgical site 1, 3
Initiation of Heparin Therapy
- Timing of initiation: Start UFH infusion ≥24 hours after surgery (usually at 24-48 hours) 1, 2, 3
- Initial dose: Initiate without bolus, with a lower-intensity infusion than the full therapeutic dose 3
Monitoring
Special Considerations
Transition to Oral Anticoagulation
- Maintain UFH until the international normalized ratio (INR) reaches the therapeutic range with warfarin (2.5-3.5 for mechanical mitral valves) 4, 6